UBS AM
TRDA icon

UBS AM’s Entrada Therapeutics TRDA Stock Holding History

UBS AM’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2K Hold
435
– – ﹤0.01% 3469
2026
Q1 		$5.49K Buy
435
+413
+1,877% +$4.73K ﹤0.01% 3446
2025
Q4 		$226 Sell
22
-89
-80% -$750 ﹤0.01% 3270
2025
Q3 		$644 Buy
+111
New +$649 ﹤0.01% 2269
2025
Q2 		– Sell
-33,593
Closed -$304K – 2717
2025
Q1 		$304K Sell
33,593
-2,157
-6% -$26.9K ﹤0.01% 2555
2024
Q4 		$618K Buy
35,750
+21,594
+153% +$391K ﹤0.01% 2515
2024
Q3 		$226K Buy
14,156
+3,644
+35% +$57.4K ﹤0.01% 2752
2024
Q2 		$150K Buy
+10,512
New +$149K ﹤0.01% 2766

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

UBS AM's TRDA Position: Q2 2026 in Review

UBS AM held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 435 shares worth $3.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

UBS AM first reported a position in TRDA in Q2 2024 and has held it in 8 quarters since. The position peaked at $618K in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • UBS AM held 435 shares of Entrada Therapeutics worth $3.2K as of Q2 2026.
  • UBS AM left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3469 holding.
  • UBS AM first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • UBS AM's Entrada Therapeutics position peaked at $618K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.